Guerbet makes the CDP A grade1 for its commitment to the fight against global warming
See the rest here:
Guerbet makes the CDP A grade for its commitment to the fight against global warming
QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette
ARESTAT™ formulated product progressing into clinical trial ARESTAT™ formulated product progressing into clinical trial
Go here to see the original:
Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development...
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1
Publication of Supplementary Prospectus
See the article here:
Publication of Supplementary Prospectus
Eliminating one of the convertible notes represents a significant milestone for Global WholeHealth Partners Corp.
See more here:
Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off One of Its Outstanding Convertible Notes
- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -
More:
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.
Read more:
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report